Skip to main content

Advertisement

Log in

Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria

Pathology & Oncology Research

Abstract

Practice and accuracy of immunohistochemistry is known to vary highly. Reliability of HER-2 immunohistochemistry is critical because of its role in patient selection for therapeutical options in breast cancer. Therefore reliability of HER-2 immunohistochemistry in pathology laboratories in Austria was assessed. Ten tissue specimens of invasive ductal breast carcinomas and three cell line samples were tested. Presence/absence of gene amplification was determined by FISH to be used as a gold standard. Laboratories were asked to stain and assess slides using their routine immunohistochemical staining protocol. Overall the study consisted of 311 tests on tissue specimens and 142 on cell lines. In all cases manual scoring was performed. Participation was voluntary and was 94%. Overall sensitivity was 90.5% and specificity 99.2%. Overscoring including true false positive results were found in 6.7% and 6.3% in tissue specimens and cell lines, respectively. False negative determinations were obtained in 1.9% and 2.8% of tissue specimens and cell lines, respectively. HercepTestTM showed slightly higher reliability in comparison with individualized staining methods. By manual scoring inaccurate scoring affected 12.3% of test results and 62% of the laboratories. In conclusion participation rate and accuracy of HER-immunohistochemistry was high all over the country. Manually performed scoring demonstrated some limitations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Abbreviations

IHC:

immunohistochemistry

FISH:

fluorescence in situ hybridization

References

  1. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43

    CAS  PubMed  Google Scholar 

  2. Gennari A, Sormani MP, Pronzato P et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14–20

    CAS  PubMed  Google Scholar 

  3. Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2356

    CAS  PubMed  Google Scholar 

  4. Konecny G, Pauletti G, Pegram M et al (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142–153

    Article  CAS  PubMed  Google Scholar 

  5. Ménard S, Valagussa P, Pilotti S et al (2001) Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 19:329–335

    PubMed  Google Scholar 

  6. Press MF, Hung G, Godolphin W et al (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771–2777

    CAS  PubMed  Google Scholar 

  7. Wang S, Saboorian MH, Frenkel EP et al (2001) Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116:495–503

    Article  CAS  PubMed  Google Scholar 

  8. Italian Network for Quality Assurance of Tumor Biomarkers (INQAT) Group; SIAPEC-IAP (2005) Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: an update from INQAT round III. Int J Biol Markers 20:189–194

    Google Scholar 

  9. Paik S, Bryant J, Tan-Chiu E et al (2002) Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852–854

    PubMed  Google Scholar 

  10. Rhodes A, Jasani B, Anderson E et al (2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118:408–417

    Article  CAS  PubMed  Google Scholar 

  11. Fleiss JG (1981) Statistical methods for rates and proportions. Wiley, New York, NY, pp 225–232

    Google Scholar 

  12. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174

    Article  CAS  PubMed  Google Scholar 

  13. Bilous M, Dowsett M, Hanna W et al (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16:173–182

    Article  PubMed  Google Scholar 

  14. Ellis IO, Bartlett J, Dowsett M et al (2004) Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 57:233–237

    Article  CAS  PubMed  Google Scholar 

  15. Bertheau P, Cazals-Hatem D, Meignin V et al (1998) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:370–374

    Article  CAS  PubMed  Google Scholar 

  16. Rhodes A, Borthwick D, Sykes R et al (2004) The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol 122:51–60

    Article  PubMed  Google Scholar 

  17. Jacobs TW, Gown AM, Yaziji H et al (1999) Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974–1982

    CAS  PubMed  Google Scholar 

  18. Lebeau A, Deimling D, Kaltz C et al (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354–63

    CAS  PubMed  Google Scholar 

  19. Tubbs RR, Pettay JD, Roche PC et al (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714–2721

    CAS  PubMed  Google Scholar 

  20. Hoang MP, Sahin AA, Ordòñez NG et al (2000) HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852–859

    Article  CAS  PubMed  Google Scholar 

  21. Thomson TA, Hayes MM, Spinelli JJ et al (2001) HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14:1079–1086

    Article  CAS  PubMed  Google Scholar 

  22. Dietel M, Ellis IO, Höfler H et al (2007) Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 51:19–25

    Article  CAS  Google Scholar 

Download references

Acknowledgment

The project was supported by a grant of the Austrian Society of Senology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Reiner-Concin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiner-Concin, A., Regitnig, P., Dinges, H.P. et al. Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria. Pathol. Oncol. Res. 14, 253–259 (2008). https://doi.org/10.1007/s12253-008-9079-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-008-9079-z

Keywords

Navigation